Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Assets Average (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Assets Average for 4 consecutive years, with $32.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 55.63% to $32.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.0 million, a 55.63% increase, with the full-year FY2023 number at $37.9 million, changed N/A from a year prior.
  • Assets Average was $32.0 million for Q4 2025 at Neuphoria Therapeutics, up from $28.0 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $37.8 million in Q2 2023 to a low of $20.5 million in Q4 2024.
  • A 4-year average of $27.7 million and a median of $26.9 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: skyrocketed 59.01% in 2023, then grew 8.27% in 2025.
  • Neuphoria Therapeutics' Assets Average stood at $23.7 million in 2022, then surged by 59.01% to $37.8 million in 2023, then crashed by 45.6% to $20.5 million in 2024, then soared by 55.63% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Assets Average are $32.0 million (Q4 2025), $28.0 million (Q3 2025), and $29.7 million (Q2 2025).